Novo Nordisk Previews EASD 2026 Data Package: Wegovy Pill Real-World OCTANE Study, Cardiometabolic Outcomes, and Next-Generation Amylin Candidates for the September 28-October 2 Milan Meeting
Novo Nordisk announced Wednesday September 16, 2026 the outline of its data presentations for the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2026 in Milan, Italy, September 28 through October 2. Real-world evidence from the OCTANE study will report Wegovy pill (oral semaglutide 25/50 mg) outcomes in adults with overweight or obesity including weight change, treatment switching patterns, and patient-reported outcomes across a large post-launch cohort. Additional EASD abstracts span obesity, type 2 diabetes, cardiovascular disease, kidney disease, and liver-related outcomes. Next-generation amylin candidate presentations include amycretin (long-acting unimolecular GLP-1/amylin dual agonist Phase 2 monotherapy and combination data) and CagriSema (cagrilintide plus semaglutide) follow-through from the earlier Redefine-1 head-to-head miss versus tirzepatide (23% vs 25.5% weight loss at 68 weeks). The EASD cluster also includes AstraZeneca AZD6234 APRICUS amylin data, Zealand-Roche petrelintide ZUPREME-2, and Roche Pharma Day September 28. Novo's Capital Markets Day in London September 21 will precede the EASD meeting by one week.